This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Molecular Cancer Open Access 18 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Turner, N. C. et al. Capivasertib in hormone receptor–positive advanced breast cancer. N. Engl J. Med. 388, 2058–2070 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Capivasertib delays disease progression. Nat Rev Clin Oncol 20, 579 (2023). https://doi.org/10.1038/s41571-023-00790-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00790-x
This article is cited by
-
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Molecular Cancer (2023)